Clinical Trial Update: Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer

View source ↗

Summary

Ongoing clinical trial evaluating how mutant p53 and YAP proteins contribute to therapy resistance in recurrent head and neck cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Snippet

Sponsor: Regina Elena Cancer Institute | Conditions: Head and Neck Tumors | Status: RECRUITING